The phase I mass balance study to investigate the pharmacokinetics of OP-724 following a single dose of 14C-labeled OP-724 in healthy male volunteers.

OHARA Pharmaceutical Co.,Ltd.0 个研究点目标入组 6 人开始时间: 2023年11月10日最近更新: 2025年1月17日

试验速览

暂无简介。

•1: Healthy Japanese male subjects.
•2: Age at the time of obtaining written informed consent is >=18 to <45 years old.
•3: Subjects who are capable of fully understanding the clinical trial and providing written informed consent.

•1: Subjects with any clinilcal abnormality assessed by the investigator or subinvestigator in laboratory tests, vital signs, or 12-lead ECG in eligibility testing.
•2: Subjects with a QTcF of > 450 msec on a 12-lead ECG in the eligibility test.
•3: Subjects who weighs < 50.0 kg in the eligibility test.

Pharmacokinetics

未报告次要终点

发起方

OHARA Pharmaceutical Co.,Ltd.